Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Jul 13;33(7):424–429. doi: 10.1002/clc.20776

Long‐Term Survival After Acute Myocardial Infarction and Relation to Type 2 Diabetes and Other Risk Factors

Mark Gruppetta 1, Neville Calleja 3, Stephen Fava 1,2,3,✉
PMCID: PMC6653194  PMID: 20641120

Abstract

Background

Diabetes mellitus (DM) is well established as a short‐term prognostic indicator after myocardial infarction (MI), but little long‐term data are available.

Hypothesis

The objective of the study was to assess the impact of DM and other patient characteristics at baseline on long‐term mortality after acute MI.

Methods

Patients who were hospitalized with MI from December 1990 to November 1992 were recruited. Baseline data were recorded and patients were followed up through January 31, 2008, to assess their survival rates. Survival curves were generated by the Kaplan‐Meier method. The main outcome measure was long‐term survival (median 16.6 y).

Results

The study followed 337 patients (mean age 66.4 y, 61.1% men) for a median of 16.6 years. Using Cox regression analysis, survival was associated with history of MI (hazard ratio [HR]: 1.47, P = 0.016), DM at baseline (HR: 1.31, P = 0.038), and age (HR: 1.061 for each additional year, P < 0.001). By multivariable regression, cardiovascular mortality was also associated with previous MI (HR: 1.58, P = 0.017), DM at baseline (HR: 1.69, P = 0.001), and age (HR: 1.075 for each additional year, P < 0.001). There was no statistically significant difference between the HRs for history of MI and history of DM.

Conclusions

Diabetic patients with MI have a higher long‐term all‐cause and cardiovascular mortality. Our data also show that in patients with MI, DM confers the same level of risk as a previous MI. This extends to patients with documented MI, our concept of diabetes being a coronary heart disease equivalent. Based on this and on data from the literature, we propose that it would be more accurate to consider DM as an MI equivalent rather than a coronary heart disease equivalent. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (156.7 KB).

References

  • 1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta‐analysis of 37 prospective cohort studies. BMJ 2008; 332: 73–78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Murcia AM, Hennekens CH, Lamas GA, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004; 164: 2273–2279. [DOI] [PubMed] [Google Scholar]
  • 3. Fava S, Azzopardi J, Muscat HA, Fenech FF. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care 1993; 16: 1615–1618. [DOI] [PubMed] [Google Scholar]
  • 4. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21: 69–75. [DOI] [PubMed] [Google Scholar]
  • 5. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI‐2 study. J Am Coll Cardiol 1993; 22: 1788–1794. [DOI] [PubMed] [Google Scholar]
  • 6. Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents: the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993; 21: 920–925. [DOI] [PubMed] [Google Scholar]
  • 7. Barbash GI, White HD, Modan M, Van de Werf F; Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 22: 707–713. [DOI] [PubMed] [Google Scholar]
  • 8. Mak KH, Moliterno DJ, Granger CB, et al; GUSTO‐I Investigators. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997; 30: 171–179. [DOI] [PubMed] [Google Scholar]
  • 9. Koek HL, Soedamah‐Muthu SS, Kardaun JW, et al. Short‐ and long‐term mortality after acute myocardial infarction: comparison of patients with and without diabetes mellitus. Eur J Epidemiol 2007; 22: 883–888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Behar S, Boyko V, Reicher‐Reiss H, Goldbourt U; SPRINT Study Group. Ten‐year survival after acute myocardial infarction: comparison of patients with and without diabetes. Secondary Prevention Reinfarction Israeli Nifedipine Trial. Am Heart J 1997; 133: 290–296. [DOI] [PubMed] [Google Scholar]
  • 11. Moen EK, Asher CR, Miller DP, et al. Long‐term follow‐up of gender‐specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO‐I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Womens Health 1997; 6: 285–293. [DOI] [PubMed] [Google Scholar]
  • 12. Mirić L, Mirić D, Duplancić D, et al. Specific and gender differences between hospitalized and out of hospital mortality due to myocardial infarction. Coll Antropol 2008; 32: 361–367. [PubMed] [Google Scholar]
  • 13. Rieves D, Wright G, Gupta G, Shacter E. Clinical trial (GUSTO‐1 and INJECT) evidence of earlier death for men than women after acute myocardial infarction. Am J Cardiol 2000; 85: 147–153. [DOI] [PubMed] [Google Scholar]
  • 14. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEJM 1998; 339: 229–234. [DOI] [PubMed] [Google Scholar]
  • 15. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow‐up. Arch Intern Med 2001; 161: 1717–1723. [DOI] [PubMed] [Google Scholar]
  • 16. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18‐year prospective population‐based study in Finnish subjects. Diabetes Care 2005; 28: 2901–2907. [DOI] [PubMed] [Google Scholar]
  • 17. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow‐up in the Renfrew and Paisley survey. Diabetes Care 2005; 28: 1588–1593. [DOI] [PubMed] [Google Scholar]
  • 18. Sington JD, Cottrell BJ. Analysis of the sensitivity of death certificates in 440 hospital deaths: a comparison with necropsy findings. J Clin Pathol 2002; 55: 499–502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Timmer JR, Ottervanger JP, de Boer MJ, et al; Primary Coronary Angioplasty vs Thrombolysis‐2 Trialists Collaborators Group. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis‐2 trial. Arch Intern Med 2007; 167: 1353–1359. [DOI] [PubMed] [Google Scholar]
  • 20. Bonnefoy E, Steg PG, Chabaud S, et al. Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction?: data from the CAPTIM randomized clinical trial. Eur Heart J 2005; 26: 1712–1718. [DOI] [PubMed] [Google Scholar]
  • 21. Madsen MM, Busk M, Søndergaard HM, et al; DANAMI‐2 Investigators. Does diabetes mellitus abolish the beneficial effect of primary coronary angioplasty on long‐term risk of reinfarction after acute ST‐segment elevation myocardial infarction compared with fibrinolysis? (A DANAMI‐2 substudy). Am J Cardiol 2005; 96: 1469–1475. [DOI] [PubMed] [Google Scholar]
  • 22. Mehta SR, Boden WE, Eikelboom JW, et al; OASIS 5 and 6 Investigators. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST‐ and non–ST‐segment elevation acute coronary syndromes: an individual patient‐level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 2008; 118: 2038–2046. [DOI] [PubMed] [Google Scholar]
  • 23. Mehta SR, Yusuf S, Díaz R, et al; CREATE‐ECLA Trial Group Investigators. Effect of glucose‐insulin‐potassium infusion on mortality in patients with acute ST‐segment elevation myocardial infarction: the CREATE‐ECLA randomized controlled trial. JAMA 2005; 293: 437–446. [DOI] [PubMed] [Google Scholar]
  • 24. Gurm HS, Lincoff AM, Lee D, et al; GUSTO V Trial. Outcome of acute ST‐segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. J Am Coll Cardiol 2004; 43: 542–548. [DOI] [PubMed] [Google Scholar]
  • 25. Stuckey TD, Stone GW, Cox DA, et al; CADILLAC Investigators. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol 2005; 95: 1–7. [DOI] [PubMed] [Google Scholar]
  • 26. Théroux P, Alexander J Jr, Pharand C, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non‐ST‐elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM‐PLUS) study. Circulation 2000; 102: 2466–2472. [DOI] [PubMed] [Google Scholar]
  • 27. Morrow DA, Antman EM, Murphy SA, et al; TIMI Study Group. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST‐elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment‐Thrombolysis In Myocardial Infarction study 25 (ExTRACT‐TIMI 25) trial. Am Heart J 2007; 154: 1078–1084. [DOI] [PubMed] [Google Scholar]
  • 28. Sinnaeve PR, Alexander JH, Bogaerts K, et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one‐year follow‐up results of the Ass essment of the Safety of a New Thrombolytic‐3 (ASSENT‐3) randomized trial in acute myocardial infarction. Am Heart J 2004; 147: 993–998. [DOI] [PubMed] [Google Scholar]
  • 29. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625–628. [DOI] [PubMed] [Google Scholar]
  • 30. Wiviott SD, Braunwald E, Angiolillo DJ, et al; TRITON‐TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel—Thrombolysis in Myocardial Infarction 38. Circulation 118: 1626–1636. [DOI] [PubMed] [Google Scholar]
  • 31. Peters RJ, Joyner C, Bassand JP, et al; OASIS‐6 Investigators. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS‐6 trial. Eur Heart J 2008; 29: 324–331. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES